Data collected from hospital workers has revealed that Bharat Biotech's COVID-19 vaccine, Covaxin, was only 50% effective at preventing symptomatic COVID-19 in a high-risk population during a devastating second wave of infections in India this year, Reuters news agency reported on Wednesday.
The real world study for Covaxin, conducted from 15 April to 15 May 2021 compares with a 77.8% effectiveness rate in a late-stage trial of more than 25,000 participants that was conducted November 2020 to January 2021.
According to the study, which was published in the Lancet Infectious Diseases journal, this new data analysed just over 1,000 COVID-19 cases with a test-negative control case group, matching by age and gender.
The study concluded that the much lower effectiveness rate for the two-dose shot seen in this new study can possibly be attributed to the fact that the study was restricted to hospital employees who had a higher risk of being infected than the general population, that it was conducted during a surge in infections and also to the prevalence of the Delta virus variant at the time.
Clover Bio announces SCB-1019 vaccine candidate Phase I trial data in initial young adult cohort
Sanofi launches Verorab for rabies prophylaxis in UK
BioVaxys expands patent portfolio for DPX delivery platform and advances DPX SurMAGE
VGXI names new chief accounting officer
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Valneva launches Phase 1 trial for next-generation Zika vaccine
Circio Holding ASA confirms licensing deal with IOVaxis Therapeutics in China and Singapore
Everest Medicines names new chief medical officer and chief product officer
Pfizer's PREVENAR 20 gains European Commission approval for paediatric pneumococcal vaccine
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV